Key facts
- This page summarizes Power Michael S. Rosol's Form 4 filing for NAVIDEA BIOPHARMACEUTICALS, INC..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 13 Sep 2022, 16:07.
Power Michael S. Rosol - 09 Sep 2022 Form 4 Insider Report for NAVIDEA BIOPHARMACEUTICALS, INC.
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 09 Sep 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Sep 2022, 16:07:44 UTC
- Prior SEC filing
- 18 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Erika L. Eves for Michael S. Rosol, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Power Michael S. Rosol filed Form 4 for NAVIDEA BIOPHARMACEUTICALS, INC. on 13 Sep 2022.
Change
- Previous filing in this sequence was filed on 18 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NAVB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +28,150
- Change %
- +193%
- Price
- $0.000000
- Shares after
- 42,725
- Date
- 09 Sep 2022
- Ownership
- Direct
- Footnotes
- F1, F2
NAVB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +13,000
- Change %
- +30%
- Price
- $0.000000
- Shares after
- 55,725
- Date
- 09 Sep 2022
- Ownership
- Direct
- Footnotes
- F2
NAVB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,320
- Date
- 09 Sep 2022
- Ownership
- Held by 401(k) Plan
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Reporting Person elected to receive stock in lieu of a cash bonus. The number of shares was determined based on the closing price on the date of grant, September 9, 2022.
Footnote F2
Stock Issued under the Amended and Restated 2014 Stock Incentive Plan.